Empagliflozin, an oral anti‐diabetic drug that inhibits the sodium‐dependent glucose co‐transporter 2 (SGLT2), has pleiotropic effects on the myocardium. The aim of the study is to investigate the effect of… Click to show full abstract
Empagliflozin, an oral anti‐diabetic drug that inhibits the sodium‐dependent glucose co‐transporter 2 (SGLT2), has pleiotropic effects on the myocardium. The aim of the study is to investigate the effect of empagliflozin on atrial electromechanical delay (AEMD) and the left atrial (LA) mechanical functions in patients with type 2 diabetes mellitus (DM).
               
Click one of the above tabs to view related content.